A New Antibody For Treating Acute Lymphocytic Leukemia?
The new agent, a monoclonal antibody to CD22 with a toxin attached, is manufactured by Pfizer. It’s called inotuzumab ozogamicin.
Elaine Schattner
writer, health care advocate, physician
writer, health care advocate, physician
The new agent, a monoclonal antibody to CD22 with a toxin attached, is manufactured by Pfizer. It’s called inotuzumab ozogamicin.